Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

AMLODIPINE vs OSIMERTINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

AMLODIPINE vs OSIMERTINIB: Safety Overview

Metric AMLODIPINE OSIMERTINIB
Total FAERS Reports 64,924 27,750
Deaths Reported 10,161 12,456
Death Rate 15.7% 44.9%
Hospitalizations 26,787 5,277
Average Patient Age 62.8 yrs 68.2 yrs
% Female Patients 57.0% 66.0%
FDA Approval Date Apr 12, 2011 Nov 13, 2015
Manufacturer Teva Pharmaceuticals USA, Inc. AstraZeneca Pharmaceuticals LP
Route ORAL ORAL
Marketing Status Prescription Prescription